
|Articles|March 4, 2014
- Vol 31 No 3
- Volume 31
- Issue 3
Data Point
Author(s)Richard M. Berlin, MD
Three years deep in despair, he’s swallowed every pill I prescribed...
Advertisement
While reviewing the results of a drug study for treatment-resistant depression
Three years deep in despair, he’s swallowed
every pill I prescribed. Refusing ECT,
his family and I convinced him to give
research medication one last shot.
Unblinded data arrived today and glows
on my computer screen, each depressed
patient’s response graphed with a dot,
the experimental molecule clearly beating
placebo, my patient’s outlier point six feet under
the rising line of success, a speck of coal
on a snow-covered field, my mind expanding
the insignificant dot to a skull’s eye socket
staring me down like a Beretta’s bullet hole.
Articles in this issue
over 12 years ago
The New CPT Codes: Ethical Challenges in a New Billing Era?over 12 years ago
End-of-Life Decisions: Who Decides and the Role of the Psychiatristover 12 years ago
Revive Flurothyl Inhalation Therapyover 12 years ago
Prescribing Psychotropics for Women of Childbearing Potentialover 12 years ago
Introduction: The Brave New World of Psychiatric Ethicsover 12 years ago
Ethics and Virtues in Clinical PsychiatryAdvertisement
Related to this article

Learn how IPV shapes mental health from pregnancy to adulthood, and how clinicians assess risk, plan safety, and treat victims and perpetrators.

Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.

Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.

A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.

Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.

Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.

Atypical psychedelics such as ketamine, MDMA, and ibogaine show fast-acting promise for depression, PTSD, and addiction beyond 5-HT2A.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
3
New Analyses of HLP003 for the Adjunctive Treatment of MDD
4
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
5

